Please login to the form below
insulin icodec
This page shows the latest insulin icodec news and features for those working in and with pharma, biotech and healthcare.
Novo Nordisk’s insulin icodec shows promise as once-weekly type 2 diabetes treatment
Insulin icodec is a novel once-weekly basal insulin analogue designed to cover the basal insulin requirements for a full week with a single subcutaneous injection. ... The trial achieved its primary endpoint of demonstrating non-inferiority in reducing
Latest news
-
Novo Nordisk’s insulin icodec shows promise as once-weekly type 2 diabetes treatment
Insulin icodec is a novel once-weekly basal insulin analogue designed to cover the basal insulin requirements for a full week with a single subcutaneous injection. ... The trial achieved its primary endpoint of demonstrating non-inferiority in reducing
-
Novo Nordisk announces positive phase 2 trial results for type 2 diabetes treatment
Last month, the company also announced positive results from the ONWARDS 3 AND ONWARDS 4 phase 3a trials with once-weekly insulin Icodec in adults with type 2 diabetes. ... The trial achieved its primary endpoint of demonstrating non-inferiority in
More from news
Approximately 1 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- Europe’s cancer community publishes new report on transforming patient care
- Eli Lilly announces $450m investment in US manufacturing site
- AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
- ASH 2022: bad blood but big advances
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- MIT researchers develop AI model to detect future lung cancer risk
- GSK’s Benlysta given orphan drug status by FDA for systemic sclerosis
- Kite and Arcellx close multiple myeloma collaboration agreement
- The challenges of identifying rare diseases
- Live Webinar: Streamlining Healthcare Delivery Through Digital Care Journeys
- Sanofi/Regeneron’s Dupixent approved by EC for eosinophilic oesophagitis
- Boehringer reports positive phase 2 data for spesolimab in generalised pustular psoriasis
- EU outlines measures to mitigate antibiotic shortage across Europe
- The challenges of identifying rare diseases
- AbbVie and Eli Lilly leave UK’s voluntary drug pricing agreement
- FDA and CDC investigate potential safety concern for Pfizer/BioNTech’s COVID-19 vaccine
- Sanofi/Regeneron’s Dupixent approved by EC for eosinophilic oesophagitis
- This month in 1917: A tale of two Mercks
PMHub
Impetus Digital
Impetus Digital has offered virtual advisory boards, clinical trial investigator consortiums, co-author publication working groups, steering committees, and medical education...
Latest intelligence
- The challenges of identifying rare diseases
- With increased awareness and improved diagnosis, more rare diseases are being recognised and this number is likely to increase in the coming years...
- 5 ways we’re enhancing our services to support our clients in 2023
- Fishawack Health CEO Jon Koch explains the new platforms, tools, and services we’re elevating to drive innovation for our clients in 2023....
- ASH 2022: bad blood but big advances
- Five trends from this year’s ASH conference – and why even pop icons can’t compete with the playlist of innovation shaping haematology...
